What amount sold does Linnaeus Therapeutics, Inc. report in Form D filings?

The latest linked filings report $21.7M sold across 6 identified offering(s). 0 unlinked amendment(s) are excluded; 0 offering(s) have no reported amount sold. This is not verified lifetime funding or money raised during a specific period.

When was Linnaeus Therapeutics, Inc.'s most recent SEC filing?

Linnaeus Therapeutics, Inc.'s most recent Form D filing was on 2026-04-02.

How many investors does Linnaeus Therapeutics, Inc. have?

The most recent Form D filing lists 26 investor(s).

What type of securities does Linnaeus Therapeutics, Inc. offer?

Linnaeus Therapeutics, Inc.'s SEC Form D filings indicate equity offerings.

Linnaeus Therapeutics, Inc.

CIK: 0001752026·Biotechnology·HADDONFIELD, NJ·Corporation

Reported Sold

$21,684,064

Total Filings

Identified Offerings

Last Filed

Apr 2, 2026

Employees

—

Reported sold uses the latest linked filing for each identified offering; it is not verified lifetime funding. SPV filings are shown separately.

About

Company in Biotechnology industry

SEC EDGAR

Offering filing timeline

Apr 2, 2026Form D/A — Amendment

Reported sold: $4,992,000 · Target: $10,000,000

Rule 506(b)·26 investors

Changed: Reported amount sold, Reported investors

Mar 31, 2026Form D/A — Amendment

Reported sold: $4,892,000 · Target: $10,000,000

Rule 506(b)·26 investors

Changed: Reported amount sold, Reported investors

Mar 13, 2026Form D/A — Amendment

Reported sold: $4,792,000 · Target: $10,000,000

Rule 506(b)·25 investors

Changed: Reported amount sold, Reported investors

Feb 27, 2026Form D — New notice

Reported sold: $4,475,000 · Target: $10,000,000

Rule 506(b)·19 investors

Aug 22, 2025Form D — New notice

Reported sold: $1,275,000 · Target: $10,000,000

Rule 506(c)·3 investors

Dec 26, 2024Form D/A — Amendment

Reported sold: $5,824,155 · Target: $6,860,000

Rule 506(b)·12 investors·Section 4(a)(5)

Changed: Reported amount sold, Offering target, Reported investors

Aug 12, 2024Form D — New notice

Reported sold: $1,628,398 · Target: $3,920,000

Rule 506(b)·6 investors·Section 4(a)(5)

Jan 26, 2023Form D — New notice

Reported sold: $3,088,234 · Target: $3,088,234

Rule 506(b)·8 investors·Section 4(a)(5)

Aug 24, 2021Form D — New notice

Reported sold: $4,344,675 · Target: $4,344,675

Rule 506(b)·15 investors·Section 4(a)(5)

Sep 7, 2018Form D — New notice

Reported sold: $2,160,000 · Target: Indefinite

Rule 506(b)·4 investors·Section 4(a)(5)

Fundraising Profile

Exemptions

Rule 506(b)

Investors in latest filing

Revenue Range

Decline to Disclose

Reported commissions across identified offerings

Amendment Rate

40%

Latest reported sold across 6 identified offerings

$21,684,064

Uses the latest linked filing for each offering. This is not a measure of money raised in the last year or verified lifetime funding.

Key People

Chris Arendt

Related Person

Appears on 7 filings

James Demetriades

Related Person

Appears on 7 filings

Patrick T. Mooney

Related Person

Appears on 6 filings

Todd T. Thomson

Related Person

Appears on 5 filings

Michael D. Poisel

Related Person

Appears on 5 filings

Michael Poisel

Related Person

Appears on 5 filings

Patrick Mooney

Related Person

Appears on 4 filings

Todd Thomson

Related Person

Appears on 4 filings

Filing History

Date	Type	Offering target	Reported sold	Investors
Apr 2, 2026	Amendment	$10,000,000	$4,992,000	26
Mar 31, 2026	Amendment	$10,000,000	$4,892,000	26
Mar 13, 2026	Amendment	$10,000,000	$4,792,000	25
Feb 27, 2026	New	$10,000,000	$4,475,000	19
Aug 22, 2025	New	$10,000,000	$1,275,000	3
Dec 26, 2024	Amendment	$6,860,000	$5,824,155	12
Aug 12, 2024	New	$3,920,000	$1,628,398	6
Jan 26, 2023	New	$3,088,234	$3,088,234	8
Aug 24, 2021	New	$4,344,675	$4,344,675	15
Sep 7, 2018	New	Indefinite	$2,160,000	4

Filing History

Amendment insights

Loading amendment history…

Comparable issuers

Matched on reported industry and issuer type, then ranked by business location, offering target, and recency. These are filing comparables, not verified business competitors.

TETmedical, Inc.

Biotechnology

Offering target: $9,812,108

Filed Jun 24, 2026